On October 11, 2024, John Adent, CEO of Neogen Corp (NEOG, Financial), purchased 14,500 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now owns a total of 216,477 shares of Neogen Corp.
Neogen Corp specializes in the development and marketing of solutions for food and animal safety. The company's products and services include diagnostics, veterinary instruments, and disinfectants among others.
Over the past year, John Adent has increased his holdings in the company by purchasing a total of 37,500 shares. There have been no sales recorded by the insider during this period. The broader insider transaction trend at Neogen Corp shows a positive sentiment, with 8 insider buys and no insider sales over the last year.
Shares of Neogen Corp were priced at $13.8 on the day of the insider's recent purchase. The company's market cap is approximately $3.2 billion. According to GF Value, the stock is currently modestly undervalued, with a price-to-GF-Value ratio of 0.81, suggesting potential for price appreciation.
The GF Value of $17.08 is derived from historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for expected business performance.
This insider buying activity could be a signal to investors about the perceived value of Neogen Corp by its CEO, especially considering the stock's current valuation metrics and the overall positive insider buying trend within the company.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
